Photo Source: FASEB J For this experiment, researchers first produced a protein-modifying spectrum of drug-resistant and non-resistant cells from pancreatic cancer cell linesBy comparing these maps, they found changes in specific protein modifications associated with drug-resistant cellsThere is PML in drug-resistant cells and is known for its involvement in an aggressive form of leukemiaUsing cultured cells, the researchers found that a change in PML modification known as ubiquitinization was also involved in pancreatic cancer cells' resistance to chemotherapy therapyUsing a patient-sourced xenotransplant model, the researchers found that higher levels of PML expression and higher levels of PML ubiquity had higher survival ratesInstead, the study showed that patients with low PML expression and PML low ubiquitinhadhad had a worse survival rate because their tumors showed resistance to chemotherapy treatment"These findings can improve the prognosis of pancreatic cancer patients in a relatively short period of time," said DrPhilippe Soubeyran, a researcher at the Maasai Cancer Research Centre (CRCM) at the French National Institute of Health and Medical Research"In the long run, we may be able to improve the treatment of pancreatic cancer by restoring the drug's efficacy against drug-resistant tumors"It's an interesting finding that the post-translation modification of this protein is so decisive, " said DrThoru Pederson, editor-in-chief of theFASEB magazineThis not only resets the therapeutic dimension, but may also indicate similar cancer protein events in other malignant tumors"
References: Philippe Soubeyran et alPML hyposumoying is responsible for the ford of the cancerThe FASEB Journal DOI: https://doi.org/10.1096/fj.201901091R
